Zeynep Yalcin

From single to dual targeting: Recent advances in EGFR-based dual inhibitors for cancer therapy.

The epidermal growth factor receptor (EGFR) is a receptor tyrosine kinase whose overexpression and activating mutations drive the pathogenesis of solid tumors, particularly non-small cell lung cancer (NSCLC). ATP-competitive EGFR inhibitors have progressed through four generations with considerable clinical success, ye...